What is MedinCell?
MedinCell operates at the intersection of advanced material science and pharmacology, utilizing its proprietary BEPO technology platform to revolutionize patient care. By creating fully bioresorbable deposits that allow for the controlled, sustained release of medication, the company addresses critical challenges in treatment adherence and therapeutic efficacy. Its market position is bolstered by the successful FDA approval of UZEDY, a risperidone-based injectable, which serves as a proof-of-concept for the platform's versatility across various therapeutic areas. As a publicly traded entity on Euronext Paris, MedinCell maintains a dual focus on scientific excellence and environmental sustainability, aiming to reduce the ecological footprint of traditional pharmaceutical delivery methods while enhancing accessibility for patients globally.
How much funding has MedinCell raised?
MedinCell has raised a total of $98.3M across 4 funding rounds:
Private Equity
$19M
Debt
$12M
Debt
$40M
Other Financing Round
$27.3M
Private Equity (2019): $19M with participation from Bill & Melinda Gates Foundation
Debt (2020): $12M, investors not publicly disclosed
Debt (2022): $40M supported by European Investment Bank
Other Financing Round (2023): $27.3M, investors not publicly disclosed
Key Investors in MedinCell
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives.
European Investment Bank
Established in 1958 and headquartered in Luxembourg, European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for MedinCell?
With the recent influx of capital, MedinCell is well-positioned to accelerate its pipeline development and expand the reach of its BEPO technology. The strategic focus will likely shift toward scaling manufacturing capabilities and pursuing new regulatory milestones for its late-stage candidates. By leveraging its established partnerships with global pharmaceutical leaders, the company is poised to transition from a specialized research firm into a broader commercial powerhouse. Future growth will be driven by the continued optimization of its long-acting injectable portfolio, ensuring that MedinCell remains at the forefront of the biopharmaceutical sector's shift toward patient-centric, sustainable drug delivery systems.
See full MedinCell company page
